
IDEX (IEX) Stock Forecast & Price Target
IDEX (IEX) Analyst Ratings
Bulls say
IDEX's diverse portfolio across three segments – fluid and metering technologies, health and science technologies, and fire and safety and diversified products – positions it favorably for future growth, particularly with health and science technologies expected to demonstrate the highest organic growth at around 3%. Notably, the firm reported organic sales growth across its segments, with FSDP rising 8% and HST increasing 8%, driven by tailwinds in life sciences and other key markets such as pharmaceuticals and energy. Furthermore, with a revenue generation of $3.3 billion in 2024 and ongoing investments in innovation and growth-friendly acquisitions, IDEX is poised to leverage its strong market demand to enhance long-term performance.
Bears say
IDEX's recent financial reports indicate a troubling trend, with revenue growth lagging behind peers during the 2016-2018 period due to the shutdown of underperforming businesses. For 2025, the company is projecting cash earnings per share (EPS) in a downside scenario that could drastically fall to approximately $6.52 to $6.88, reflecting anticipated organic revenue declines and pressure on operating margins. Furthermore, the first quarter of 2025 guidance has been notably weak, with expectations of a 4% to 3% decline in organic sales, along with a 19% miss relative to consensus, driven by stock compensation impacts and non-recurring revenues from previous projects.
This aggregate rating is based on analysts' research of IDEX and is not a guaranteed prediction by Public.com or investment advice.
IDEX (IEX) Analyst Forecast & Price Prediction
Start investing in IDEX (IEX)
Order type
Buy in
Order amount
Est. shares
0 shares